TW200716630A - Pyrazolo[1,5-a] pyridine derivative or medically acceptable salt thereof - Google Patents

Pyrazolo[1,5-a] pyridine derivative or medically acceptable salt thereof

Info

Publication number: TW200716630A
Authority: TW; Taiwan
Prior art keywords: pyrazolo; acceptable salt; pyridine derivative; medically acceptable; mapkap
Prior art date: 2005-04-07

Application number

TW095112463A

Other languages

English (en)

Inventor

Gen Unoki

Yoshiyuki Matsumoto

Yohei Matsueda

Motoko Hamada

Tomomi Kosugi

Mika Takakuwa

Hiroaki Makino

Kenichiro Kataoka

Yuko Yamakoshi

Original Assignee

Teijin Pharma Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-04-07

Filing date

2006-04-07

Publication date

2007-05-01

2006-04-07 Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd

2007-05-01 Publication of TW200716630A publication Critical patent/TW200716630A/zh

Links

DVUBDHRTVYLIPA-UHFFFAOYSA-N pyrazolo[1,5-a]pyridine Chemical class C1=CC=CN2N=CC=C21 DVUBDHRTVYLIPA-UHFFFAOYSA-N 0.000 title abstract 2
150000003839 salts Chemical class 0.000 title abstract 2
102100034069 MAP kinase-activated protein kinase 2 Human genes 0.000 abstract 2
101710141394 MAP kinase-activated protein kinase 2 Proteins 0.000 abstract 2
208000023275 Autoimmune disease Diseases 0.000 abstract 1
208000020084 Bone disease Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
230000005907 cancer growth Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000001066 destructive effect Effects 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
230000004614 tumor growth Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Psychiatry (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Dermatology (AREA)
Epidemiology (AREA)

TW095112463A 2005-04-07 2006-04-07 Pyrazolo[1,5-a] pyridine derivative or medically acceptable salt thereof TW200716630A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2005111419		2005-04-07
JP2005254677		2005-09-02

Publications (1)

Publication Number	Publication Date
TW200716630A true TW200716630A (en)	2007-05-01

Family

ID=37087129

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW095112463A TW200716630A (en)	2005-04-07	2006-04-07	Pyrazolo[1,5-a] pyridine derivative or medically acceptable salt thereof

Country Status (8)

Country	Link
EP (1)	EP1873154A4 (zh)
JP (1)	JPWO2006109867A1 (zh)
KR (1)	KR20080002935A (zh)
AU (1)	AU2006234618A1 (zh)
BR (1)	BRPI0607907A2 (zh)
CA (1)	CA2603457A1 (zh)
TW (1)	TW200716630A (zh)
WO (1)	WO2006109867A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW201341367A (zh) *	2012-03-16	2013-10-16	Axikin Pharmaceuticals Inc	３，５－二胺基吡唑激酶抑制劑

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2001139575A (ja) *	1999-11-15	2001-05-22	Fujisawa Pharmaceut Co Ltd	新規ピラゾロピリジン誘導体
WO2003087087A2 (en) *	2002-04-09	2003-10-23	Astex Technology Limited	Heterocyclic compounds and their use as modulators of p38 map kinase
WO2004026872A1 (en) *	2002-09-19	2004-04-01	Schering Corporation	Pyrazolopyridines as cyclin dependent kinase inhibitors
GB0305559D0 (en) *	2003-03-11	2003-04-16	Teijin Ltd	Compounds
US7700773B2 (en) *	2005-09-09	2010-04-20	Schering Corporation	4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridines, pyrazolo[1,5-c]pyrimidines and 2H-indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridines, and imidazo[1,5-a]pyrazines as cyclin dependent kinase inhibitors

2006
- 2006-04-07 BR BRPI0607907A patent/BRPI0607907A2/pt not_active IP Right Cessation
- 2006-04-07 KR KR1020077025890A patent/KR20080002935A/ko not_active Withdrawn
- 2006-04-07 EP EP06731826A patent/EP1873154A4/en not_active Withdrawn
- 2006-04-07 JP JP2007513040A patent/JPWO2006109867A1/ja not_active Withdrawn
- 2006-04-07 AU AU2006234618A patent/AU2006234618A1/en not_active Abandoned
- 2006-04-07 TW TW095112463A patent/TW200716630A/zh unknown
- 2006-04-07 CA CA002603457A patent/CA2603457A1/en not_active Abandoned
- 2006-04-07 WO PCT/JP2006/307890 patent/WO2006109867A1/ja not_active Ceased

Also Published As

Publication number	Publication date
KR20080002935A (ko)	2008-01-04
EP1873154A4 (en)	2010-08-18
EP1873154A1 (en)	2008-01-02
CA2603457A1 (en)	2006-10-19
JPWO2006109867A1 (ja)	2008-11-20
WO2006109867A1 (ja)	2006-10-19
AU2006234618A1 (en)	2006-10-19
BRPI0607907A2 (pt)	2016-11-08

Publication	Publication Date	Title
TN2012000062A1 (en)	2013-09-19	Jak 2 inhibitors and their use for the treatment of myeloproliferative deseases and cancer
WO2007044085A3 (en)	2007-06-28	Heteroaryl compounds and their uses as therapeutic agents
WO2006067445A3 (en)	2006-09-14	Csf-1r kinase inhibitors
WO2007061764A3 (en)	2007-11-15	Tricyclic compounds useful as inhibitors of kinases
SG11201408052WA (en)	2015-01-29	IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS
AU2011338389A8 (en)	2013-07-18	Bicyclic compounds as Pim inhibitors
TN2009000439A1 (en)	2011-03-31	Substituted benzoylamino-indian-2-carboxylic acids and related compounds
NZ613219A (en)	2014-11-28	Heterocyclic containing entities, compositions and methods
MX2010014233A (es)	2011-03-25	Compuestos quimicos 251.
TW200615266A (en)	2006-05-16	Organic compounds
JO3265B1 (ar)	2018-09-16	مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
MX2009011615A (es)	2009-11-10	Acidos benzoilamino-indan-2-carboxilicos sustituidos y compuestos relacionados.
TW200716648A (en)	2007-05-01	Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
MX2007008924A (es)	2007-08-21	Compuestos quimicos.
MX2009004908A (es)	2009-05-19	Compuestos quimicos.
WO2006072589A3 (en)	2006-10-12	Disubstituted ureas as kinase inhibitors
WO2007071963A3 (en)	2007-08-09	Quinazoline derivatives, process for their preparation and their use as anti-cancer agents
WO2007046868A3 (en)	2007-07-12	Thiazolidine derivatives and their uses as therapeutic agents
WO2009022185A3 (en)	2009-07-09	6, 6-fused heterocycles, their pharmaceutical compositions and methos of use
NZ592429A (en)	2012-10-26	PHENANTHROINDOLIZIDINE DERIVATIVE AND NFkB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT
WO2007046867A3 (en)	2007-07-05	Piperidine derivatives and their uses as therapeutic agents
BR0307588A (pt)	2005-02-01	Composto, inibidor de gsk-3, composição farmacêutica, e, agente terapêutico ou preventivo para uma doença
WO2007024843A3 (en)	2007-08-09	Pyrimidinyl-pyrazole inhibitors of aurora kinases
TW200745136A (en)	2007-12-16	4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid derivatives
MX2024005766A (es)	2024-07-29	Compuesto de imidazo[4,5-b]piridina cristalina, composiciones farmacéuticas y su uso en el tratamiento de condiciones médicas.